Total Payments
$2.7M
2024 Payments
$341,100
Companies
55
Transactions
3,804
Medicare Patients
9,354
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$2.0M (75.6%)
Consulting$255,978 (9.4%)
Travel$198,065 (7.3%)
Research$126,004 (4.6%)
Food & Beverage$80,198 (3.0%)
Education$1,219 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.0M | 709 | 72.5% |
| Consulting Fee | $255,978 | 116 | 9.4% |
| Travel and Lodging | $198,065 | 589 | 7.3% |
| Unspecified | $126,004 | 83 | 4.6% |
| Honoraria | $81,080 | 29 | 3.0% |
| Food and Beverage | $80,198 | 2,251 | 3.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,800 | 1 | 0.1% |
| Education | $1,219 | 26 | 0.0% |
Payments by Type
General
$2.6M
3,721 transactions
Research
$126,004
83 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $339,249 | 442 | $0 (2024) |
| ABBVIE INC. | $332,058 | 479 | $0 (2024) |
| Incyte Corporation | $276,903 | 256 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $233,751 | 272 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $226,895 | 303 | $0 (2024) |
| GENZYME CORPORATION | $223,916 | 224 | $0 (2024) |
| Janssen Biotech, Inc. | $160,980 | 259 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $148,615 | 205 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $113,516 | 155 | $0 (2024) |
| Amgen Inc. | $109,446 | 125 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $341,100 | 513 | Janssen Biotech, Inc. ($58,625) |
| 2023 | $482,977 | 637 | Janssen Biotech, Inc. ($95,564) |
| 2022 | $322,998 | 449 | Incyte Corporation ($108,258) |
| 2021 | $139,845 | 238 | AbbVie Inc. ($31,541) |
| 2020 | $201,872 | 301 | Lilly USA, LLC ($35,354) |
| 2019 | $433,828 | 604 | AbbVie, Inc. ($86,290) |
| 2018 | $377,462 | 478 | Novartis Pharmaceuticals Corporation ($90,083) |
| 2017 | $409,975 | 584 | Regeneron Healthcare Solutions, Inc. ($110,227) |
All Payment Transactions
3,804 individual payment records from CMS Open Payments — Page 1 of 153
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/28/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $30.42 | General |
| 12/24/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $3.88 | General |
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.19 | General |
| Category: Immunology | ||||||
| 12/21/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: DERMATOLOGY | ||||||
| 12/20/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $3.47 | General |
| Category: DERMATOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.05 | General |
| Category: Immunology | ||||||
| 12/14/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | — | Food and Beverage | In-kind items and services | $31.50 | General |
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.29 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Inflammation | ||||||
| 12/06/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,040.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $1,344.62 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $144.90 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: DERMATOLOGY | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: Immunology | ||||||
| 11/30/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $17.55 | General |
| 11/30/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $14.72 | General |
| 11/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,253.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $44,306 | 3 |
| GBR830-204 | Ichnos Sciences Inc. | $35,236 | 20 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $32,323 | 41 |
| Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES) | Almirall LLC | $4,687 | 2 |
| ISB830-204 | Ichnos Sciences Inc. | $4,344 | 1 |
| PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED SINGLE-ARM PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB | Eli Lilly and Company | $3,320 | 1 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $1,288 | 14 |
| A MULTICENTER, OPEN LABEL, SINGLE-ARM STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF EFINACONAZOLE 10 TOPICAL SOLUTION IN SUBJECTS WITH MILD TO SEVERE ONYCHOMYCOSIS OF THE TOENAILS | Bausch Health US, LLC | $500.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 2,257 | 4,094 | $1.0M | $273,456 |
| 2022 | 22 | 2,708 | 5,598 | $1.5M | $434,370 |
| 2021 | 23 | 2,570 | 5,373 | $1.6M | $462,779 |
| 2020 | 22 | 1,819 | 3,433 | $946,079 | $241,730 |
Total Patients
9,354
Total Services
18,498
Medicare Billing
$1.4M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 635 | 1,188 | $300,514 | $81,916 | 27.3% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 14 | 349 | $101,261 | $39,129 | 38.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 260 | 350 | $115,953 | $35,707 | 30.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 367 | 367 | $137,705 | $28,214 | 20.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 221 | 297 | $91,958 | $28,129 | 30.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 173 | 188 | $69,078 | $13,946 | 20.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 92 | 92 | $44,221 | $12,521 | 28.3% |
| 17360 | Chemical treatment of acne | Office | 2023 | 39 | 82 | $22,906 | $8,598 | 37.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 87 | 134 | $31,342 | $5,939 | 18.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 53 | 70 | $11,547 | $3,426 | 29.7% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 55 | 77 | $16,825 | $3,144 | 18.7% |
| 10040 | Acne surgery | Office | 2023 | 36 | 38 | $11,906 | $3,085 | 25.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 71 | 503 | $45,715 | $2,920 | 6.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 34 | 49 | $9,290 | $2,217 | 23.9% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 18 | 35 | $6,009 | $1,841 | 30.6% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 14 | 14 | $5,896 | $1,339 | 22.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 15 | 15 | $3,296 | $804.08 | 24.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 37 | $1,573 | $419.97 | 26.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 58 | 209 | $4,621 | $161.58 | 3.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 704 | 1,568 | $401,719 | $121,868 | 30.3% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2022 | 27 | 574 | $129,150 | $67,293 | 52.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 512 | 512 | $206,281 | $47,830 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 242 | 373 | $107,705 | $40,588 | 37.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 261 | 404 | $111,130 | $40,517 | 36.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 220 | 258 | $111,665 | $21,246 | 19.0% |
About Dr. Jeffrey Weinberg, MD
Dr. Jeffrey Weinberg, MD is a Dermatology healthcare provider based in Kew Gardens, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689660565.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Weinberg, MD has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $341,100 received in 2024. These payments were reported across 3,804 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.0M).
As a Medicare-enrolled provider, Weinberg has provided services to 9,354 Medicare beneficiaries, totaling 18,498 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Kew Gardens, NY
- Active Since 09/26/2005
- Last Updated 05/19/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1689660565
Products in Payments
- TALTZ (Drug) $353,081
- OPZELURA (Drug) $252,428
- COSENTYX (Biological) $224,032
- Otezla (Drug) $201,251
- TREMFYA (Drug) $169,821
- Humira (Biological) $150,135
- DUPIXENT DUPILUMAB INJECTION (Biological) $149,271
- DUPIXENT (Biological) $138,877
- SKYRIZI (Biological) $115,576
- Sotyktu (Drug) $96,428
- ILUMYA (Biological) $86,873
- ATOPIC DERMATITIS - DISEASE (Drug) $75,038
- DUPIXENT (Drug) $73,422
- VTAMA (Drug) $62,030
- EUCRISA (Drug) $47,295
- Bimzelx (Biological) $43,502
- ILUMYA (tildrakizumab-asmn) injection (Biological) $40,631
- GBR830-204 (Drug) $35,236
- RINVOQ (Biological) $21,338
- LITFULO (Drug) $19,818
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.